Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

DVAX – Dynavax Technologies Corporation

Dynavax Technologies Corporatio
DVAX
$9.91
Name : Dynavax Technologies Corporatio
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $1,190,002,688.00
EPSttm : -0.5
finviz dynamic chart for DVAX
Dynavax Technologies Corporatio
$9.91
0.30%
$0.03

Float Short %

13.26

Margin Of Safety %

-18

Put/Call OI Ratio

0.14

EPS Next Q Diff

0.3

EPS Last/This Y

-0.63

EPS This/Next Y

0.88

Price

9.9

Target Price

23.27

Analyst Recom

2

Performance Q

-27.77

Relative Volume

2.11

Beta

1.04

Ticker: DVAX




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02DVAX9.840.912.9212240
2025-06-03DVAX10.020.913.0012284
2025-06-04DVAX9.890.920.1212322
2025-06-05DVAX9.950.920.1412329
2025-06-06DVAX10.250.9216.0012338
2025-06-09DVAX10.280.853.8612846
2025-06-10DVAX10.430.850.3112912
2025-06-11DVAX10.180.840.0013099
2025-06-12DVAX10.40.840.0013113
2025-06-13DVAX10.270.840.0013134
2025-06-16DVAX10.160.842.9113141
2025-06-17DVAX9.980.840.0313188
2025-06-18DVAX10.290.841.8913197
2025-06-20DVAX9.980.840.6913229
2025-06-23DVAX9.760.120.066889
2025-06-24DVAX9.90.121.397203
2025-06-25DVAX9.860.13999.997319
2025-06-26DVAX9.930.130.907339
2025-06-27DVAX9.90.140.447382
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02DVAX9.8575.0- -0.42
2025-06-03DVAX10.0175.0- -0.42
2025-06-04DVAX9.8875.0- -0.42
2025-06-05DVAX9.9575.0- -0.42
2025-06-06DVAX10.2475.0- -0.42
2025-06-09DVAX10.2875.0- -0.42
2025-06-10DVAX10.4375.0- -0.42
2025-06-11DVAX10.1875.0- -0.42
2025-06-12DVAX10.4075.0- -0.42
2025-06-13DVAX10.2775.0- -0.42
2025-06-16DVAX10.1775.0- -0.42
2025-06-17DVAX9.9875.0- -0.42
2025-06-18DVAX10.3075.0- -0.42
2025-06-20DVAX9.9975.0- -0.42
2025-06-23DVAX9.7775.0- -0.42
2025-06-24DVAX9.9075.0- -0.42
2025-06-25DVAX9.8575.0- -0.42
2025-06-26DVAX9.9375.0- -0.42
2025-06-27DVAX9.9075.0- -0.42
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02DVAX-1.00-2.1513.40
2025-06-03DVAX-1.00-2.1513.40
2025-06-04DVAX-1.00-2.1513.40
2025-06-05DVAX-1.00-2.1513.40
2025-06-06DVAX-1.00-2.1513.40
2025-06-09DVAX-1.00-2.1413.40
2025-06-10DVAX-1.00-2.1413.40
2025-06-11DVAX-1.00-2.1413.80
2025-06-12DVAX-1.00-2.1413.80
2025-06-13DVAX-1.00-2.1413.80
2025-06-16DVAX-1.00-2.3013.80
2025-06-18DVAX-1.00-2.3013.80
2025-06-20DVAX-0.99-2.3013.81
2025-06-23DVAX-0.99-2.1113.81
2025-06-24DVAX-0.99-2.1113.81
2025-06-25DVAX-0.99-2.1113.81
2025-06-26DVAX-0.99-2.1113.26
2025-06-27DVAX-0.99-2.1113.26
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.11

Avg. EPS Est. Current Quarter

0.14

Avg. EPS Est. Next Quarter

0.19

Insider Transactions

-0.99

Institutional Transactions

-2.11

Beta

1.04

Average Sales Estimate Current Quarter

87

Average Sales Estimate Next Quarter

95

Fair Value

8.14

Quality Score

51

Growth Score

51

Sentiment Score

7

Actual DrawDown %

53.7

Max Drawdown 5-Year %

-68.1

Target Price

23.27

P/E

Forward P/E

18.61

PEG

P/S

4.04

P/B

2.31

P/Free Cash Flow

22.03

EPS

-0.53

Average EPS Est. Cur. Y​

-0.42

EPS Next Y. (Est.)

0.46

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-20.39

Relative Volume

2.11

Return on Equity vs Sector %

-35.2

Return on Equity vs Industry %

-18.6

EPS 1 7Days Diff

-0.4

EPS 1 30Days Diff

-0.75

EBIT Estimation

Dynavax Technologies Corporatio
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 405
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
stock quote shares DVAX – Dynavax Technologies Corporation Stock Price stock today
news today DVAX – Dynavax Technologies Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch DVAX – Dynavax Technologies Corporation yahoo finance google finance
stock history DVAX – Dynavax Technologies Corporation invest stock market
stock prices DVAX premarket after hours
ticker DVAX fair value insiders trading